The poor prognosis and high mortality associated with pancreatic cancer is largely attributed to late detection of the disease. Most cases present themselves at an advanced or metastatic stage, making it difficult to resect the tumor or control its spread. Early detection and diagnosis would mitigate this and help in improving survival. However, due to the low incidence and prevalence of this cancer, screening is recommended only for individuals at high risk due to familial cases of pancreatic cancer. Current early detection includes imaging modalities like EUS and MRI/MRCP (National Comprehensive Cancer Network, 2023) . Some of the accepted biomarkers and risk factors for pancreatic cancer are listed in Table . Biomarker needs for pancreatic cancer can be divided into three aspects: